COLLAGENASE SANTYL ◊ ointment 250 units/g [SMITH & NEPHEW, INC]

Manufacturer
SMITH & NEPHEW, INC | Renaissance Lakewood LLC | HALO PHARMACEUTICALS, INC. | Smith & Nephew, Inc.
Effective date
2019-05-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:28:51

Label at a glance#

ProductCOLLAGENASE SANTYL
Active ingredientCOLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Label structure12 sections

Indications and uses

Collagenase Santyl ◊  Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21

Dosage and administration

Collagenase Santyl ◊  Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl ◊  Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santy...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Collagenase Santyl◊ Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of detritus. 1   Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. 2, 3, 4, 5, 6 Collagen in healthy tissue or in newly formed granulation tissue is not attacked. 2, 3, 4, 5, 6, 7, 8 There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Collagenase Santyl◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Collagenase Santyl◊ Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

PRECAUTIONS

PRECAUTIONS SECTION

The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme’s activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase Santyl◊ Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin’s solution and normal saline are compatible with Collagenase Santyl◊ Ointment.

Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia.

A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase Santyl◊ Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported.

OVERDOSAGE

OVERDOSAGE SECTION

No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Collagenase Santyl◊ Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl◊ Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl◊ Ointment in the following manner:

1 - Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl◊ Ointment (See PRECAUTIONS ), followed by a normal saline solution rinse.

2 - Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl◊ Ointment. Should the infection not respond, therapy with Collagenase Santyl◊ Ointment should be discontinued until remission of the infection.

3 - Collagenase Santyl◊ Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

4 - Use of Collagenase Santyl◊ Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.

HOW SUPPLIED

HOW SUPPLIED SECTION

Collagenase Santyl◊ Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP.

Do not store above 25°C (77°F). Sterility guaranteed until tube is opened.

Collagenase Santyl◊ Ointment is available in the following sizes:

30 g tube NDC 50484-010-30

90 g tube NDC 50484-010-90

REFERENCES

1 – Mandl, I., Adv Enzymol. 23:163, 1961.

2 – Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75, 1969.

3 – Mazurek, I., Med. Welt. 22:150, 1971.

4 – Zimmermann, WE., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185.

5 – Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975.

6 – Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975.

7 – Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974.

8 – Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973.

9 – German, F. M., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165.

10 – Haimovici, H. & Strauch, B., in “Collagenase,” Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177.

11 – Lee, L.K., & Ambrus, J.L., Geriatrics. 30:91, 1975.

12 – Locke, R.K., & Heifitz, N.M., J. Am. Pod. Assoc. 65:242, 1975.

13 – Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973.

14 – Barrett, D., Jr., & Klibanski, A., Am. J. Nurs. 73:849, 1973.

15 – Bardfeld, L.A., J. Pod. Ed. 1:41, 1970.

16 – Blum, G., Schweiz, Rundschau Med Praxis. 62:820, 1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36.

17 – Zaruba, F., Lettl, A., Brozkova, L., Skrdlantova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:499, 1974.

18 – Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978.

19 – Rehn, V.J., Med. Klin. 58:799, 1963.

20 – Krauss, H., Koslowski, L., & Zimmermann, W. E., Langenbecks Arch. Klin. Chir. 303:23, 1963.

21 – Gruenagel, H.H., Med. Klin. 58:442, 1963.

Manufactured by:
SMITH & NEPHEW, INC
Fort Worth, Texas 76109

US Gov’t License #2004

Marketed by:
Smith & Nephew◊

1-800-441-8227

Smith & Nephew, Inc.,
Fort Worth, Texas 76109

© 2016 Smith & Nephew, Inc.

SANTYL is a registered trademark of Smith & Nephew, Inc.

140749-0316

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

2228603f-figure-01
2228603f-figure-01

TUBE LABEL.PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

2228603f-figure-02
2228603f-figure-02

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309509collagenase 250 UNT per GM Topical OintmentPSN3
309509collagenase 0.25 UNT/MG Topical OintmentSCD3
309509collagenase 250 UNT per GM Topical OintmentSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
COLLAGENASE Pharmacologic Class Indexing1Indexing - Pharmacologic Class20101101

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fec04153-5a73-4a89-81d8-454536caa49fProduct name120210119

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50484-010-30COLLAGENASE SANTYL30 g in 1 TUBEOINTMENT303
50484-010-30COLLAGENASE SANTYL1 in 1 CARTONOINTMENT13
50484-010-90COLLAGENASE SANTYL1 in 1 CARTONOINTMENT13
50484-010-90COLLAGENASE SANTYL90 g in 1 TUBEOINTMENT903

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50484-010COLLAGENASE SANTYL OINTMENT [SMITH & NEPHEW, INC]3Current NDC, Legacy NDC, 4 package rows20190521_6b6fbfc6-98fa-46aa-88ef-ab00fbb08ffd.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50484-010-30GM - Gram50484-010bc0f0ce4-60e0-4e62-b4e0-5e4c319a8afb12016-07-19
50484-010-90GM - Gram50484-01056be641a-f3d9-4379-8f98-f28747ef131712016-02-04

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
COLLAGENASE CLOSTRIDIUM HISTOLYTICUMACTIVE INGREDIENT9X7O8V25IT1
COLLAGENASE CLOSTRIDIUM HISTOLYTICUMACTIVE MOIETY9X7O8V25IT1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50484-01050484-010-30, 50484-010-90

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
101995Santylcollagenase351(a)Rx2026-09-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 3 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / TOPICAL7275 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / TOPICAL7275 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / TOPICAL7275 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
COLLAGENASE SANTYLCOLLAGENASE SANTYLSMITH & NEPHEW, INC6b6fbfc6-98fa-46aa-88ef-ab00fbb08ffd2019-05-17Adverse reactionsExact identifier
ndc (package): 50484-010-30
ndc (package): 50484-010-90
ndc (product): 50484-010
ndc11 (package): 50484001090
ndc11 (package): 50484001030
spl id: 155959d1-0367-4fb6-8877-29099d08801c
spl set id: 6b6fbfc6-98fa-46aa-88ef-ab00fbb08ffd

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.